IYH vs XLV

Key Takeaways

• Both ETFs provide U.S. healthcare sector exposure but differ structurally: IYH tracks the broader Russell 1000 Health Care RIC 22.5/45 Capped Index with 103 holdings, while XLV follows the S&P 500-focused Health Care Select Sector Index with 60 holdings.
• XLV offers superior cost efficiency at 0.08% expense ratio versus IYH's 0.38%, enhancing long-term net returns for cost-conscious investors.
• XLV demonstrates higher liquidity with average daily volume exceeding 8 million shares and $36.6 billion AUM, compared to IYH's 450,000 shares and $2.75 billion AUM.
• IYH provides greater diversification, including mid-cap exposure, while XLV concentrates on large-cap S&P 500 healthcare firms, leading to similar top holdings like LLY and JNJ.
• Subsector tilts vary: IYH emphasizes biotechnology (21.6%) more than XLV (18.4%), while XLV has higher health care providers allocation (19.4% vs. IYH's managed health care at 9.3%).
• Recent performance shows tight tracking, with both down around 6-7% YTD amid sector rotation, but XLV's scale supports tighter bid-ask spreads (0.01% vs. 0.02%).

Introduction

Healthcare ETFs like iShares U.S. Healthcare ETF (IYH) and State Street Health Care Select Sector SPDR ETF (XLV) offer investors targeted exposure to a defensive sector known for resilient demand amid economic cycles. These funds compete indirectly within U.S. healthcare, with IYH providing broader market coverage beyond S&P 500 constituents and XLV delivering precise large-cap benchmarking. Their comparison gains relevance in the current environment of interest rate uncertainty and sector rotation toward defensives, where structural differences in diversification, costs, and liquidity influence portfolio positioning. Investors seeking healthcare allocation can weigh IYH's mid-cap tilt against XLV's efficiency and scale for optimized sector exposure.

iShares U.S. Healthcare ETF (IYH) Overview

The iShares U.S. Healthcare ETF (IYH) is a passively managed fund seeking to track the Russell 1000 Health Care RIC 22.5/45 Capped Index, which includes U.S. equities in the healthcare sector with caps to limit concentration (no single stock over 22.5% or top five over 45%). It holds 103 stocks, offering broader exposure across large-, mid-, and smaller-cap names. Top holdings include LLY (14.1%), JNJ (9.9%), ABBV (6.6%), UNH (6.4%), and MRK (5.2%), comprising about 57% of assets. Subsector allocations feature pharmaceuticals (36.1%), biotechnology (21.6%), health care equipment (16.6%), and life sciences tools (9.1%). The expense ratio is 0.38%, with AUM at $2.75 billion and 30-day median bid-ask spread of 0.02%. IYH rebalances periodically per index methodology, emphasizing diversified healthcare access.

State Street Health Care Select Sector SPDR ETF (XLV) Overview

The State Street Health Care Select Sector SPDR ETF (XLV) is a passive ETF tracking the Health Care Select Sector Index, representing healthcare companies from the S&P 500. It maintains 60 holdings, focusing on large-cap leaders. Top holdings mirror sector giants: LLY (14.8%), JNJ (10.3%), ABBV (6.9%), UNH (6.7%), and MRK (5.3%), accounting for roughly 59% of the portfolio. Industry weights include pharmaceuticals (36.6%), health care providers & services (19.4%), biotechnology (18.4%), and equipment & supplies (16.7%). With a low expense ratio of 0.08%, $36.6 billion AUM, and 30-day median bid-ask spread of 0.01%, XLV excels in liquidity (daily volume ~2.5 million shares). It rebalances quarterly to align with the S&P 500 sector composition.

Industry and Thematic Backdrop

The U.S. healthcare sector, encompassing pharmaceuticals, biotech, providers, and equipment, benefits from inelastic demand driven by aging demographics and innovation in treatments like GLP-1 drugs. Recent catalysts include resolved drug pricing uncertainties and strong ETF inflows ($6.8 billion globally in late 2025), fueling a Q4 rebound despite YTD pressures from policy overhangs and rate sensitivity. Capital flows favor defensives amid volatility, with healthcare ETFs attracting assets for lower beta (around 0.6). Risks persist from regulatory scrutiny on pricing, M&A (mergers and acquisitions) barriers, and clinical trial outcomes, alongside macroeconomic shifts like inflation impacting reimbursements. Sector rotation toward quality growth positions healthcare favorably in uncertain cycles.

Performance and Positioning Comparison

In recent months, both IYH and XLV have navigated healthcare's YTD decline of approximately 6-7%, reflecting broader sector rotation away from defensives early in 2026 amid equity rallies. Over the past year, returns hover around 9%, with XLV slightly trailing due to its large-cap purity amid mid-cap resilience in IYH. Volatility profiles align closely (3-year standard deviation ~14%), but IYH's broader holdings introduce modest mid-cap beta, enhancing upside in growth phases like biotech rallies. XLV's S&P 500 focus ties performance to mega-caps' earnings cycles, such as LLY's momentum, while interest rate expectations favor lower-duration healthcare over cyclicals. Relative positioning favors XLV for liquidity in volatile markets, with both benefiting from sector tailwinds like innovation pipelines.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like healthcare ETFs. Explore it today to uncover comparative insights on funds like IYH and XLV.

Tickeron AI Verdict

Tickeron’s AI currently favors XLV due to its superior cost efficiency (0.08% expense ratio), massive scale ($36.6B AUM), and unmatched liquidity, which support consistent tracking and lower trading frictions. While IYH offers enhanced diversification via mid-caps and a capped structure mitigating concentration risk, XLV's large-cap focus aligns with prevailing sector momentum in pharmaceuticals and providers, evidenced by relative stability in recent market cycles. Probabilistic edge tilts 65/35 toward XLV for most sector allocations, barring specific mid-cap biotech tilts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations